Health and Social Care Committee

Availability of Orkambi on the NHS inquiry

Inquiry status: Concluded

The Committee took oral evidence from representatives of NHS England, NICE and Vertex Pharmaceuticals, as well as from representatives of patients and clinicians, on Thursday 7 March 2019.

Following that session, the Committee Chair, Dr Sarah Wollaston, wrote to the Secretary of State on behalf of the Committee, setting out the Committee's view on the negotiations for the provision of Orkambi on the NHS.

The Committee was pleased to receive in October 2019 letters from NHS England and from Vertex, reporting that an agreement had been reached to make Orkambi, and other Vertex drugs for cystic fibrosis, available on the NHS.

Scope of the inquiry

The Committee’s inquiry concentrated on the provision and pricing of Orkambi, and other drugs developed by Vertex Pharmaceuticals for the treatment of cystic fibrosis. The Committee considered the positions taken in the negotiations between Vertex and NHS England, and NICE’s assessment of the cost-effectiveness of these drugs.

Latest evidence

  • 07 Mar 2019 - Availability of Orkambi on the NHS - oral evidence | PDF version (PDF379 KB) HC 1808 | Published 11 Mar 2019

    Evidence given by A patient representative nominated by the Cystic Fibrosis Trust, a clinician representative nominated by the Cystic Fibrosis TrustProfessor Stephen Powis, National Medical Director, John Stewart, National Director, Specialised Commissioning, NHS England, Sir Andrew Dillon, Chief Executive, Meindert Boysen, Director of the Centre for Health Technology Evaluation, NICEDr Jeff Leiden, Chairman, President and Chief Executive Officer, Stuart A. Arbuckle, Executive Vice President and Chief Commercial Officer, Vertex Pharmaceuticals

    Watch this evidence session

Receive RSS updates

Share this page